ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 2680 • ACR Convergence 2024

    Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE

    Omer Pamuk1, Jessica Fitzpatrick2, Jing Li3, Gabriela Schmajuk4 and Marina Magrey5, 1University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 2University California, San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a very heterogeneous presentation. Thrombocytopenia (TP) is an infrequent presentation in patients with SLE…
  • Abstract Number: 0108 • ACR Convergence 2024

    Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)

    Fernanda Oliveira de Andrade Lopes1, Andreia Coimbra Sousa2, Massimo Radin3, Gustavo Balbi4, Irene Cecchi3, Savino Sciascia5, Flavio Victor Signorelli6 and Danieli Andrade2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2University of São Paulo, São Paulo, SP, Brazil, 3University of Turin, Turin, Italy, 4Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, 5University of Turin, Torino, Turin, Italy, 6Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
  • Abstract Number: 0357 • ACR Convergence 2024

    Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves

    Clifton Bingham1, Emily Molina2, Amy Praestgaard3, Stefano Fiore3 and David Cella4, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Sanofi, Bridgewater, NJ, 4Northwestern University, Chicago, IL

    Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with…
  • Abstract Number: 0583 • ACR Convergence 2024

    Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

    Alexis Ogdie1, Philip Mease2, Francois Nantel3, Frederic Lavie4, Mohamed Sharaf5, Emmanouil Rampakakis6, Helena Marzo-Ortega7 and Laure Gossec8, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 3Nantel MedSci Consult, Montreal, QC, Canada, 4Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 5Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 6McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 7NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 8Sorbonne Université, Paris, France

    Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…
  • Abstract Number: 0682 • ACR Convergence 2024

    Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project

    Alain Lescoat1, Yen Chen2, Susan Murphy3, Nadia Vann2, Neda Kortam2, Rosemary Gedert2, Sue Farrington4, Yannick Allanore5, David Cella6, Lorinda Chung7, Philip Clements8, Christopher Denton9, Francesco Del Galdo10, Oliver Distler11, Monique Hinchcliff12, Michael Hughes13, Laura Hummers14, John Pauling15, Janet Pope16, Virginia Steen17, John Varga2, Peter Merkel18, Maya H. Buch19 and Dinesh Khanna2, and all CRISTAL collaborators, 1CHU Rennes - University Rennes 1, Rennes, France, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Plymouth, MI, 4Scleroderma & Raynaud UK, London, United Kingdom, 5Université Paris Cité, Paris, France, 6Northwestern University, Chicago, IL, 7Stanford University, Woodside, CA, 8United States, Los Angeles, CA, 9University College London, Northwood, United Kingdom, 10University of Leeds, Leeds, United Kingdom, 11Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 12Yale School of Medicine, Westport, CT, 13Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, 14Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 15North Bristol NHS Trust, Bristol, United Kingdom, 16University of Western Ontario, London, ON, Canada, 17Georgetown University School of Medicine, Washington, DC, 18University of Pennsylvania, Philadelphia, PA, 19Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

    Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures available to assess symptoms…
  • Abstract Number: 1027 • ACR Convergence 2024

    Evaluation of Health Disparities in Outcomes of Patients with Juvenile Idiopathic Arthritis

    Julia Harris1, Jade Singleton2 and Sheetal Vora3, 1Children's Mercy Kansas City, Overland Park, KS, 2Seattle Children's Hospital, Seattle, 3Atrium Health Levine Children's Hospital, Charlotte, NC

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease complicated by significant morbidity and disability with suboptimal rates of prolonged remission, decreased health-related quality…
  • Abstract Number: 1333 • ACR Convergence 2024

    Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study

    Orit Schieir1, Marie-France Valois2, Gilles Boire3, Louis Bessette4, Carter Thorne5, Susan Bartlett2, Glen Hazlewood6, Carol Hitchon7, Diane Tin5, Hugues Allard-Chamard8, Bindee Kuriya9, Janet Pope10 and Vivian Bykerk11, and on behalf of CATCH Investigators, 1McGill University, Montreal, QC, Canada, 2Centre for Outcomes Research & Eval, Montreal, QC, Canada, 3Retired, Sherbrooke, QC, Canada, 4University of Laval, Quebec City, QC, Canada, 5Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8University of Sherbrooke, Sherbrooke, QC, Canada, 9University of Toronto, Toronto, Canada, 10University of Western Ontario, London, ON, Canada, 11Hospital For Special Surgery, New York, NY

    Background/Purpose: Despite advances in early RA diagnosis and therapies, treatment outcomes can still vary considerably. Our objective was to compare short and long-term disease control…
  • Abstract Number: 1558 • ACR Convergence 2024

    Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry

    Maurizio Cutolo1, Elvis Hysa2, Nathalie Berghen3, Tessa Dufour4, Andrea Cere5, Kaat Wyckstandt3, Emanuele Gotelli1 and vanessa smith6, 1Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, 2Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, 3University of Ghent, Ghent, Italy, 4University Hospital Ghent, Gent, Belgium, 5University of Ghent, Ghent, Belgium, 6Ghent University Hospital, Gent, Belgium

    Background/Purpose: Skin involvement is a prominent feature of systemic sclerosis (SSc). The reliability of non-invasive tools such as high frequency skin ultrasound (HFSU) and durometry,…
  • Abstract Number: 2064 • ACR Convergence 2024

    Quantifying Cutaneous Dermatomyositis: A Novel 3D Image-based Approach

    Nantakarn Pongtarakulpanit1, Tanya Chandra1, shiri keret2, Eugenia Gkiaouraki3, Vladimir Liarski1, Dana Ascherman3, Siamak Mogahadam1, Chester Oddis1 and Rohit Aggarwal4, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Rapid advancement in image analysis now has a critical role in the diagnosis and assessment of skin lesions. The current standard of visual examination…
  • Abstract Number: 2328 • ACR Convergence 2024

    Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?

    Fadi Kharouf1, Virginia Carrizo Abarza2, Shangyi Gao3, Daniel Pereira4, Richard Cook5, Vinod Chandran6 and Dafna Gladman7, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5University of Waterloo, Waterloo, Canada, 6University of Toronto, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
  • Abstract Number: L06 • ACR Convergence 2023

    Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

    Kathryn Torok1, Paulina Horvei1, Franziska Rosser1, Kirsten Rose-felker2, Vibha Sood2, Adam Olsen2, Nicole Hogue2, Vickie Vandergrift2, Lauren Farver2, Devin Mcguire2, Jonathan Li3, Haley Havrilla2, Jessie Alexander4, Shawna McIntyre2 and Paul Szabolcs1, 1University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Stanford Children's Hospital, Palo Alto, CA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
  • Abstract Number: L19 • ACR Convergence 2023

    A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

    George Spencer-Green1, David Hunter2, Thomas Schnitzer3, Sheue-Fang Shih4, Tien-Tzu Tai4, Cathy Kao4 and Siao-Ning Huang4, 1Taiwan Liposome Company, Cambridge, MA, 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Taiwan Liposome Company, Taipei, Taiwan (Republic of China)

    Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
  • Abstract Number: 0362 • ACR Convergence 2023

    Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis

    Danielle Bullock1, Ilir Agalliu2, Evin Rothschild2, Kaveh Ardalan3, Erica Lawson4, Natoshia Cunningham5, William Soulsby4, Nicole Reitz6, Laura Bouslaugh7, Anna Diggs8, Elizabeth Kessler9, Sara Kramer1, Bhupinder Nahal4, Cassandra Davis10, Ashley Kemp1, Riley O'Connor1, Tiffany Chinn4, Kathy Nguyen4, Paige Hill1 and Tamar Rubinstein11, 1University of Minnesota, Minneapolis, MN, 2Albert Einstein College of Medicine, Bronx, NY, 3Duke University School of Medicine, Durham, NC, 4University of California San Francisco, San Francisco, CA, 5Michigan State University, Grand Rapids, MI, 6CARRA, Allendale, MI, 7CARRA, Washington, DC, 8CARRA, Tipton, MO, 9Spectrum Health, Grand Rapids, MI, 10University of Utah, Salt Lake City, UT, 11Albert Einstein College of Medicine, Children's Hospital at Montefiore, White Plains, NY

    Background/Purpose: Adverse childhood events (ACEs) are common in children. ACEs are various stressors, including, but not limited to parental incarceration or food and housing insecurity.…
  • Abstract Number: 0850 • ACR Convergence 2023

    Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis

    Andrea Fava1, Mohamed G. Atta1, Jose Monroy-Trujillo2, Derek Fine2, Daniel Goldman3, Izmirly peter4, H Michael Belmont5, the Accelerating Medicines Partnership in RA/SLE6, Jill Buyon7 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins School of Medicine, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 4NYU, New York, NY, 5NYU School of Medicine, New York, NY, 6Multiple, Multiple, 7NYU Grossman School of Medicine, New York, NY

    Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…
  • Abstract Number: 1172 • ACR Convergence 2023

    Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse

    Hideaki Tsuji1, Fabricio Espinosa-Ortega2, Maryam Dastmalchi2, Ingrid Lundberg2 and Karin Lodin3, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden

    Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology